Keyword: Venclexta (venetoclax)
With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.
Months after trial deaths prompted the FDA to halt study enrollment for AbbVie’s Venclexta, the agency will give the drug another shot.
In May, AbbVie and Roche scored an approval for Venclexta and Gazyva in CLL. Tuesday, they rolled out the data that helped get them there.
With ASCO ending, it's time to round up our favorite quotes from the weekend. Read on to see the most colorful things pharma executives had to say.
AbbVie and Roche’s Venclexta may have recently hit a stumbling block—but in chronic lymphocytic leukemia, it’s rolling.
The FDA is dishing on the data that prompted it to halt enrollment for a multiple myeloma trial of a combination containing Venclexta.
AbbVie and Roche are looking to move Venclexta deeper into the blood cancer arena, but their multiple myeloma ambitions just took a hit.
AbbVie and Roche’s Venclexta is leaving familiar territory with its latest nod. And to establish itself on its new turf, it’ll have to duke it out with some Big Pharma rivals.
Over the first nine months of 2018, the Illinois pharma has paid just 4.5% of the income taxes it shelled out over the same period last year.
AbbVie and Roche aim to drive further into the chronic lymphocytic leukemia market, and they’re pairing their newer drugs to do it.